TuHURA Biosciences (NASDAQ:HURA) Announces Quarterly Earnings Results, Beats Expectations By $0.04 EPS

TuHURA Biosciences (NASDAQ:HURA) posted its earnings results on Friday. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.04, FiscalAI reports.

TuHURA Biosciences Price Performance

NASDAQ HURA traded down $0.06 during trading hours on Friday, reaching $1.39. The company’s stock had a trading volume of 371,851 shares, compared to its average volume of 853,995. The firm has a market capitalization of $88.58 million, a price-to-earnings ratio of -2.57 and a beta of -0.23. TuHURA Biosciences has a 1-year low of $0.41 and a 1-year high of $3.43. The company has a debt-to-equity ratio of 0.20, a current ratio of 0.18 and a quick ratio of 0.18. The company’s 50-day moving average is $1.93 and its two-hundred day moving average is $2.00.

Wall Street Analyst Weigh In

HURA has been the subject of several recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Thursday, October 15th. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of TuHURA Biosciences in a report on Tuesday, October 27th. Finally, Citizens Jmp restated a “market outperform” rating and set a $9.00 price target on shares of TuHURA Biosciences in a research report on Tuesday, August 18th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $9.00.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical-stage biotechnology company developing immunotherapies for cancer. Its research focuses on treatments intended to stimulate the immune system and address mechanisms that allow tumors to evade immune attack. The company’s pipeline includes IFx-2.0, an investigational intratumoral immunotherapy being studied for use with checkpoint inhibitors, as well as antibody programs targeting immune-regulating pathways. TuHURA has no marketed products, and its candidates remain in development.